SAN DIEGO, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2012. Revenues for 2012 were $17.5 million, compared with revenues of $30.0 million for 2011, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of TransVax™, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients. In 2011, Vical received a $25.0 million upfront license payment from Astellas. In 2012, Vical received a $10.0 million milestone license payment and increased contract revenues from Astellas driven by delivery of clinical trial material for planned TransVax™ trials. The net loss for 2012 was $22.9 million, or $0.27 per share, compared with a net loss of $7.3 million, or $0.10 per share, for 2011. The increase in net loss for 2012 was primarily a result of the lower license revenue partially offset by higher net contract revenue under the Astellas agreements. Vical had cash and investments of approximately $86 million at year-end 2012. The net cash burn of approximately $19 million for 2012, excluding cash from financing activities, was within the projected range. The company is projecting net cash burn for the first half of 2013, excluding cash from financing activities, of between $18 million and $20 million. The projected net cash burn includes spending for long-lead-time activities such as manufacturing, validation and others that the company believes will allow timely filing of a Biologics License Application (BLA) assuming success in its lead development program, Allovectin ® immunotherapy for patients with metastatic melanoma. The company intends to provide net cash burn guidance for the remainder of the year after the release of Phase 3 results. Program highlights include: Allovectin ®
- In the company's Phase 3 registration trial of Allovectin ® vs. chemotherapy in patients with metastatic melanoma, the company conducted a comprehensive sweep in September 2012 of all active clinical sites to eliminate any time lag in death event reporting. The sweep confirmed that the target number of events had not been reached. It also confirmed the steady progress towards that goal.
- An independent Safety Monitoring Board (SMB) for the Phase 3 trial completed its final review of comprehensive trial safety data in the third quarter and reported "no basis for any concern that there is undue risk" associated with Allovectin ®.
- The company is tracking progress toward the Phase 3 secondary endpoint (overall survival) for both arms together in a blinded fashion. Independent assessment and adjudication of patient-by-patient data for the primary endpoint (response rate at 24 weeks or more after randomization) is approaching completion. Upon reaching the target number of death events, the databases for both endpoints will be unblinded simultaneously and top-line results for both endpoints are expected to be released in mid-2013.
- Astellas is planning to initiate a Phase 3 trial of TransVax™ for hematopoietic stem cell transplant (HSCT) recipients and to initiate a Phase 2 trial of TransVax™ for solid organ transplant (SOT) recipients in the first half of 2013.
- The company is planning to initiate a Phase 1/2 clinical trial of its Vaxfectin ®-formulated therapeutic vaccine against herpes simplex virus type 2 (HSV-2) in the second half of 2013.
- At the 15th Annual Meeting of the American Society of Gene & Cell Therapy in May 2012, Vical presented results from multiple animal studies with the company's Vaxfectin ®-formulated vaccines against HSV-2 demonstrating proof of concept.
- Results from the company's completed mouse studies with the HSV-2 vaccines were published in The Journal of General Virology.
- Results from the company's completed guinea pig studies with the HSV-2 vaccines were published in Vaccine.
- During the first quarter of 2012, the Naval Medical Research Center (NMRC) initiated a Phase 1 clinical trial of a tetravalent dengue DNA vaccine formulated with Vaxfectin ®. Vical manufactured the vaccine and the adjuvant for both the preclinical and clinical studies, and is providing regulatory and clinical expertise to NMRC for the dengue program.
- Researchers at Ehime University in Japan and their collaborators developed a Vaxfectin ®-formulated DNA vaccine candidate with the potential to prevent transmission of malaria and published encouraging initial results in Vaccine. Vical provided the DNA vaccine plasmid backbone and the adjuvant used in the research.
- In September 2012, Vical entered into a worldwide, nonexclusive license with Bristol-Myers Squibb Company of Vical's patented platform DNA immunization technology and its Vaxfectin ® adjuvant for use in the production of antibodies.
- In December 2012, Vical entered into a worldwide, nonexclusive license of the Vaxfectin ® adjuvant to Cyvax, Inc., a privately held vaccine development company, for use in malaria vaccines.
|Selected Condensed Financial Information (Unaudited)|
|Statements of Operations||Three Months Ended Dec. 31,||Twelve Months Ended Dec. 31,|
|(in thousands, except per share amounts)||2012||2011||2012||2011|
|Contract and grant revenue||$ 1,909||$ 1,616||$ 6,176||$ 4,223|
|License and royalty revenue||410||316||11,343||25,795|
|Research and development||3,439||3,971||17,340||17,975|
|Manufacturing and production||3,797||2,570||13,055||10,267|
|General and administrative||2,659||2,437||10,557||9,598|
|Total operating expenses||9,895||8,978||40,952||37,840|
|Loss from operations||(7,576)||(7,046)||(23,433)||(7,822)|
|Net investment and other income||27||432||534||539|
|Net loss||$ (7,549)||$ (6,614)||$ (22,899)||$ (7,283)|
|Basic and diluted net loss per share||$ (0.09)||$ (0.09)||$ (0.27)||$ (0.10)|
|Shares used to calculate basic and diluted net loss per share||86,504||72,126||85,966||72,031|
|Balance Sheets (in thousands)||December 31, 2012||December 31, 2011|
|Cash, cash equivalents, and marketable securities, including restricted||$ 83,857||$ 50,427|
|Other current assets||2,152||3,130|
|Total current assets||86,009||53,557|
|Property and equipment, net||5,284||6,226|
|Total assets||$ 96,522||$ 68,773|
|Liabilities and stockholders' equity:|
|Current liabilities||$ 5,779||$ 6,461|
|Total liabilities and stockholders' equity||$ 96,522||$ 68,773|
CONTACT: Alan R. Engbring Executive Director, Investor Relations Jill M. Broadfoot Senior Vice President and Chief Financial Officer (858) 646-1127 Website: www.vical.com